Specifically, we assessed changes in patients’ clinical measures and medication costs associated with the conversion from insulin glargine to insulin detemir for basal blood glucose control among veterans seeking care in the VA diagnosed with type 2 diabetes. The gene discussed is INS; the disease is type 2 diabetes mellitus.